

# Global Long-Acting Insulin Analogue Market Growth 2022-2028

<https://marketpublishers.com/r/G53C322AE487EN.html>

Date: December 2022

Pages: 95

Price: US\$ 3,660.00 (Single User License)

ID: G53C322AE487EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global market for Long-Acting Insulin Analogue is estimated to increase from US\$ million in 2021 to reach US\$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Long-Acting Insulin Analogue market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Long-Acting Insulin Analogue market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Long-Acting Insulin Analogue market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Long-Acting Insulin Analogue market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Long-Acting Insulin Analogue players cover Novo Nordisk, Sanofi, Eli Lilly and Company, Gan and Lee Pharmaceuticals and The United Laboratories International Holdings and etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

## Report Coverage

This latest report provides a deep insight into the global Long-Acting Insulin Analogue market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Long-Acting Insulin Analogue market, with both quantitative and qualitative data, to help readers understand how the Long-Acting Insulin Analogue market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

### Market Segmentation:

The study segments the Long-Acting Insulin Analogue market and forecasts the market size by Type (Insulin Glargine, Insulin Detemir and Insulin Degludec), by Application (Type 2 Diabetes, Type 1 Diabetes, Gestational Diabetes and Other Diabetes), and region (APAC, Americas, Europe, and Middle East & Africa).

### Segmentation by type

Insulin Glargine

Insulin Detemir

Insulin Degludec

### Segmentation by application

Type 2 Diabetes

Type 1 Diabetes

Gestational Diabetes

Other Diabetes

Segmentation by region

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

Major companies covered

Novo Nordisk

Sanofi

Eli Lilly and Company

Gan and Lee Pharmaceuticals

The United Laboratories International Holdings

Tonghua Dongbao Pharmaceutical

Chapter Introduction

Chapter 1: Scope of Long-Acting Insulin Analogue, Research Methodology, etc.

Chapter 2: Executive Summary, global Long-Acting Insulin Analogue market size (sales and revenue) and CAGR, Long-Acting Insulin Analogue market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.

Chapter 3: Long-Acting Insulin Analogue sales, revenue, average price, global market share, and industry ranking by company, 2017-2022

Chapter 4: Global Long-Acting Insulin Analogue sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.

Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.

Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace

Chapter 10: Manufacturing cost structure analysis

Chapter 11: Sales channel, distributors, and customers

Chapter 12: Global Long-Acting Insulin Analogue market size forecast by region, by country, by type, and application.

Chapter 13: Comprehensive company profiles of the leading players, including Novo Nordisk, Sanofi, Eli Lilly and Company, Gan and Lee Pharmaceuticals, The United Laboratories International Holdings and Tonghua Dongbao Pharmaceutical, etc.

Chapter 14: Research Findings and Conclusion

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Long-Acting Insulin Analogue Annual Sales 2017-2028
  - 2.1.2 World Current & Future Analysis for Long-Acting Insulin Analogue by Geographic Region, 2017, 2022 & 2028
  - 2.1.3 World Current & Future Analysis for Long-Acting Insulin Analogue by Country/Region, 2017, 2022 & 2028
- 2.2 Long-Acting Insulin Analogue Segment by Type
  - 2.2.1 Insulin Glargine
  - 2.2.2 Insulin Detemir
  - 2.2.3 Insulin Degludec
- 2.3 Long-Acting Insulin Analogue Sales by Type
  - 2.3.1 Global Long-Acting Insulin Analogue Sales Market Share by Type (2017-2022)
  - 2.3.2 Global Long-Acting Insulin Analogue Revenue and Market Share by Type (2017-2022)
  - 2.3.3 Global Long-Acting Insulin Analogue Sale Price by Type (2017-2022)
- 2.4 Long-Acting Insulin Analogue Segment by Application
  - 2.4.1 Type 2 Diabetes
  - 2.4.2 Type 1 Diabetes
  - 2.4.3 Gestational Diabetes
  - 2.4.4 Other Diabetes
- 2.5 Long-Acting Insulin Analogue Sales by Application
  - 2.5.1 Global Long-Acting Insulin Analogue Sale Market Share by Application (2017-2022)
  - 2.5.2 Global Long-Acting Insulin Analogue Revenue and Market Share by Application (2017-2022)

2.5.3 Global Long-Acting Insulin Analogue Sale Price by Application (2017-2022)

### **3 GLOBAL LONG-ACTING INSULIN ANALOGUE BY COMPANY**

3.1 Global Long-Acting Insulin Analogue Breakdown Data by Company

3.1.1 Global Long-Acting Insulin Analogue Annual Sales by Company (2020-2022)

3.1.2 Global Long-Acting Insulin Analogue Sales Market Share by Company (2020-2022)

3.2 Global Long-Acting Insulin Analogue Annual Revenue by Company (2020-2022)

3.2.1 Global Long-Acting Insulin Analogue Revenue by Company (2020-2022)

3.2.2 Global Long-Acting Insulin Analogue Revenue Market Share by Company (2020-2022)

3.3 Global Long-Acting Insulin Analogue Sale Price by Company

3.4 Key Manufacturers Long-Acting Insulin Analogue Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Long-Acting Insulin Analogue Product Location Distribution

3.4.2 Players Long-Acting Insulin Analogue Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

### **4 WORLD HISTORIC REVIEW FOR LONG-ACTING INSULIN ANALOGUE BY GEOGRAPHIC REGION**

4.1 World Historic Long-Acting Insulin Analogue Market Size by Geographic Region (2017-2022)

4.1.1 Global Long-Acting Insulin Analogue Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Long-Acting Insulin Analogue Annual Revenue by Geographic Region

4.2 World Historic Long-Acting Insulin Analogue Market Size by Country/Region (2017-2022)

4.2.1 Global Long-Acting Insulin Analogue Annual Sales by Country/Region (2017-2022)

4.2.2 Global Long-Acting Insulin Analogue Annual Revenue by Country/Region

4.3 Americas Long-Acting Insulin Analogue Sales Growth

4.4 APAC Long-Acting Insulin Analogue Sales Growth

4.5 Europe Long-Acting Insulin Analogue Sales Growth

#### 4.6 Middle East & Africa Long-Acting Insulin Analogue Sales Growth

### **5 AMERICAS**

#### 5.1 Americas Long-Acting Insulin Analogue Sales by Country

5.1.1 Americas Long-Acting Insulin Analogue Sales by Country (2017-2022)

5.1.2 Americas Long-Acting Insulin Analogue Revenue by Country (2017-2022)

#### 5.2 Americas Long-Acting Insulin Analogue Sales by Type

#### 5.3 Americas Long-Acting Insulin Analogue Sales by Application

#### 5.4 United States

#### 5.5 Canada

#### 5.6 Mexico

#### 5.7 Brazil

### **6 APAC**

#### 6.1 APAC Long-Acting Insulin Analogue Sales by Region

6.1.1 APAC Long-Acting Insulin Analogue Sales by Region (2017-2022)

6.1.2 APAC Long-Acting Insulin Analogue Revenue by Region (2017-2022)

#### 6.2 APAC Long-Acting Insulin Analogue Sales by Type

#### 6.3 APAC Long-Acting Insulin Analogue Sales by Application

#### 6.4 China

#### 6.5 Japan

#### 6.6 South Korea

#### 6.7 Southeast Asia

#### 6.8 India

#### 6.9 Australia

#### 6.10 China Taiwan

### **7 EUROPE**

#### 7.1 Europe Long-Acting Insulin Analogue by Country

7.1.1 Europe Long-Acting Insulin Analogue Sales by Country (2017-2022)

7.1.2 Europe Long-Acting Insulin Analogue Revenue by Country (2017-2022)

#### 7.2 Europe Long-Acting Insulin Analogue Sales by Type

#### 7.3 Europe Long-Acting Insulin Analogue Sales by Application

#### 7.4 Germany

#### 7.5 France

#### 7.6 UK



7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa Long-Acting Insulin Analogue by Country

8.1.1 Middle East & Africa Long-Acting Insulin Analogue Sales by Country (2017-2022)

8.1.2 Middle East & Africa Long-Acting Insulin Analogue Revenue by Country (2017-2022)

8.2 Middle East & Africa Long-Acting Insulin Analogue Sales by Type

8.3 Middle East & Africa Long-Acting Insulin Analogue Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Long-Acting Insulin Analogue

10.3 Manufacturing Process Analysis of Long-Acting Insulin Analogue

10.4 Industry Chain Structure of Long-Acting Insulin Analogue

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Long-Acting Insulin Analogue Distributors

11.3 Long-Acting Insulin Analogue Customer

## **12 WORLD FORECAST REVIEW FOR LONG-ACTING INSULIN ANALOGUE BY**

## **GEOGRAPHIC REGION**

- 12.1 Global Long-Acting Insulin Analogue Market Size Forecast by Region
  - 12.1.1 Global Long-Acting Insulin Analogue Forecast by Region (2023-2028)
  - 12.1.2 Global Long-Acting Insulin Analogue Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Long-Acting Insulin Analogue Forecast by Type
- 12.7 Global Long-Acting Insulin Analogue Forecast by Application

## **13 KEY PLAYERS ANALYSIS**

- 13.1 Novo Nordisk
  - 13.1.1 Novo Nordisk Company Information
  - 13.1.2 Novo Nordisk Long-Acting Insulin Analogue Product Offered
  - 13.1.3 Novo Nordisk Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.1.4 Novo Nordisk Main Business Overview
  - 13.1.5 Novo Nordisk Latest Developments
- 13.2 Sanofi
  - 13.2.1 Sanofi Company Information
  - 13.2.2 Sanofi Long-Acting Insulin Analogue Product Offered
  - 13.2.3 Sanofi Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.2.4 Sanofi Main Business Overview
  - 13.2.5 Sanofi Latest Developments
- 13.3 Eli Lilly and Company
  - 13.3.1 Eli Lilly and Company Company Information
  - 13.3.2 Eli Lilly and Company Long-Acting Insulin Analogue Product Offered
  - 13.3.3 Eli Lilly and Company Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2022)
  - 13.3.4 Eli Lilly and Company Main Business Overview
  - 13.3.5 Eli Lilly and Company Latest Developments
- 13.4 Gan and Lee Pharmaceuticals
  - 13.4.1 Gan and Lee Pharmaceuticals Company Information
  - 13.4.2 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product Offered

13.4.3 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Gan and Lee Pharmaceuticals Main Business Overview

13.4.5 Gan and Lee Pharmaceuticals Latest Developments

13.5 The United Laboratories International Holdings

13.5.1 The United Laboratories International Holdings Company Information

13.5.2 The United Laboratories International Holdings Long-Acting Insulin Analogue Product Offered

13.5.3 The United Laboratories International Holdings Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 The United Laboratories International Holdings Main Business Overview

13.5.5 The United Laboratories International Holdings Latest Developments

13.6 Tonghua Dongbao Pharmaceutical

13.6.1 Tonghua Dongbao Pharmaceutical Company Information

13.6.2 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product Offered

13.6.3 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Tonghua Dongbao Pharmaceutical Main Business Overview

13.6.5 Tonghua Dongbao Pharmaceutical Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Long-Acting Insulin Analogue Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)

Table 2. Long-Acting Insulin Analogue Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)

Table 3. Major Players of Insulin Glargine

Table 4. Major Players of Insulin Detemir

Table 5. Major Players of Insulin Degludec

Table 6. Global Long-Acting Insulin Analogue Sales by Type (2017-2022) & (K Units)

Table 7. Global Long-Acting Insulin Analogue Sales Market Share by Type (2017-2022)

Table 8. Global Long-Acting Insulin Analogue Revenue by Type (2017-2022) & (\$ million)

Table 9. Global Long-Acting Insulin Analogue Revenue Market Share by Type (2017-2022)

Table 10. Global Long-Acting Insulin Analogue Sale Price by Type (2017-2022) & (US\$/Unit)

Table 11. Global Long-Acting Insulin Analogue Sales by Application (2017-2022) & (K Units)

Table 12. Global Long-Acting Insulin Analogue Sales Market Share by Application (2017-2022)

Table 13. Global Long-Acting Insulin Analogue Revenue by Application (2017-2022)

Table 14. Global Long-Acting Insulin Analogue Revenue Market Share by Application (2017-2022)

Table 15. Global Long-Acting Insulin Analogue Sale Price by Application (2017-2022) & (US\$/Unit)

Table 16. Global Long-Acting Insulin Analogue Sales by Company (2020-2022) & (K Units)

Table 17. Global Long-Acting Insulin Analogue Sales Market Share by Company (2020-2022)

Table 18. Global Long-Acting Insulin Analogue Revenue by Company (2020-2022) (\$ Millions)

Table 19. Global Long-Acting Insulin Analogue Revenue Market Share by Company (2020-2022)

Table 20. Global Long-Acting Insulin Analogue Sale Price by Company (2020-2022) & (US\$/Unit)

Table 21. Key Manufacturers Long-Acting Insulin Analogue Producing Area Distribution

and Sales Area

Table 22. Players Long-Acting Insulin Analogue Products Offered

Table 23. Long-Acting Insulin Analogue Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Long-Acting Insulin Analogue Sales by Geographic Region (2017-2022) & (K Units)

Table 27. Global Long-Acting Insulin Analogue Sales Market Share Geographic Region (2017-2022)

Table 28. Global Long-Acting Insulin Analogue Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 29. Global Long-Acting Insulin Analogue Revenue Market Share by Geographic Region (2017-2022)

Table 30. Global Long-Acting Insulin Analogue Sales by Country/Region (2017-2022) & (K Units)

Table 31. Global Long-Acting Insulin Analogue Sales Market Share by Country/Region (2017-2022)

Table 32. Global Long-Acting Insulin Analogue Revenue by Country/Region (2017-2022) & (\$ millions)

Table 33. Global Long-Acting Insulin Analogue Revenue Market Share by Country/Region (2017-2022)

Table 34. Americas Long-Acting Insulin Analogue Sales by Country (2017-2022) & (K Units)

Table 35. Americas Long-Acting Insulin Analogue Sales Market Share by Country (2017-2022)

Table 36. Americas Long-Acting Insulin Analogue Revenue by Country (2017-2022) & (\$ Millions)

Table 37. Americas Long-Acting Insulin Analogue Revenue Market Share by Country (2017-2022)

Table 38. Americas Long-Acting Insulin Analogue Sales by Type (2017-2022) & (K Units)

Table 39. Americas Long-Acting Insulin Analogue Sales Market Share by Type (2017-2022)

Table 40. Americas Long-Acting Insulin Analogue Sales by Application (2017-2022) & (K Units)

Table 41. Americas Long-Acting Insulin Analogue Sales Market Share by Application (2017-2022)

Table 42. APAC Long-Acting Insulin Analogue Sales by Region (2017-2022) & (K Units)

Table 43. APAC Long-Acting Insulin Analogue Sales Market Share by Region (2017-2022)

Table 44. APAC Long-Acting Insulin Analogue Revenue by Region (2017-2022) & (\$ Millions)

Table 45. APAC Long-Acting Insulin Analogue Revenue Market Share by Region (2017-2022)

Table 46. APAC Long-Acting Insulin Analogue Sales by Type (2017-2022) & (K Units)

Table 47. APAC Long-Acting Insulin Analogue Sales Market Share by Type (2017-2022)

Table 48. APAC Long-Acting Insulin Analogue Sales by Application (2017-2022) & (K Units)

Table 49. APAC Long-Acting Insulin Analogue Sales Market Share by Application (2017-2022)

Table 50. Europe Long-Acting Insulin Analogue Sales by Country (2017-2022) & (K Units)

Table 51. Europe Long-Acting Insulin Analogue Sales Market Share by Country (2017-2022)

Table 52. Europe Long-Acting Insulin Analogue Revenue by Country (2017-2022) & (\$ Millions)

Table 53. Europe Long-Acting Insulin Analogue Revenue Market Share by Country (2017-2022)

Table 54. Europe Long-Acting Insulin Analogue Sales by Type (2017-2022) & (K Units)

Table 55. Europe Long-Acting Insulin Analogue Sales Market Share by Type (2017-2022)

Table 56. Europe Long-Acting Insulin Analogue Sales by Application (2017-2022) & (K Units)

Table 57. Europe Long-Acting Insulin Analogue Sales Market Share by Application (2017-2022)

Table 58. Middle East & Africa Long-Acting Insulin Analogue Sales by Country (2017-2022) & (K Units)

Table 59. Middle East & Africa Long-Acting Insulin Analogue Sales Market Share by Country (2017-2022)

Table 60. Middle East & Africa Long-Acting Insulin Analogue Revenue by Country (2017-2022) & (\$ Millions)

Table 61. Middle East & Africa Long-Acting Insulin Analogue Revenue Market Share by Country (2017-2022)

Table 62. Middle East & Africa Long-Acting Insulin Analogue Sales by Type (2017-2022) & (K Units)

Table 63. Middle East & Africa Long-Acting Insulin Analogue Sales Market Share by

Type (2017-2022)

Table 64. Middle East & Africa Long-Acting Insulin Analogue Sales by Application (2017-2022) & (K Units)

Table 65. Middle East & Africa Long-Acting Insulin Analogue Sales Market Share by Application (2017-2022)

Table 66. Key Market Drivers & Growth Opportunities of Long-Acting Insulin Analogue

Table 67. Key Market Challenges & Risks of Long-Acting Insulin Analogue

Table 68. Key Industry Trends of Long-Acting Insulin Analogue

Table 69. Long-Acting Insulin Analogue Raw Material

Table 70. Key Suppliers of Raw Materials

Table 71. Long-Acting Insulin Analogue Distributors List

Table 72. Long-Acting Insulin Analogue Customer List

Table 73. Global Long-Acting Insulin Analogue Sales Forecast by Region (2023-2028) & (K Units)

Table 74. Global Long-Acting Insulin Analogue Sales Market Forecast by Region

Table 75. Global Long-Acting Insulin Analogue Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 76. Global Long-Acting Insulin Analogue Revenue Market Share Forecast by Region (2023-2028)

Table 77. Americas Long-Acting Insulin Analogue Sales Forecast by Country (2023-2028) & (K Units)

Table 78. Americas Long-Acting Insulin Analogue Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 79. APAC Long-Acting Insulin Analogue Sales Forecast by Region (2023-2028) & (K Units)

Table 80. APAC Long-Acting Insulin Analogue Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 81. Europe Long-Acting Insulin Analogue Sales Forecast by Country (2023-2028) & (K Units)

Table 82. Europe Long-Acting Insulin Analogue Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 83. Middle East & Africa Long-Acting Insulin Analogue Sales Forecast by Country (2023-2028) & (K Units)

Table 84. Middle East & Africa Long-Acting Insulin Analogue Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 85. Global Long-Acting Insulin Analogue Sales Forecast by Type (2023-2028) & (K Units)

Table 86. Global Long-Acting Insulin Analogue Sales Market Share Forecast by Type (2023-2028)



Table 87. Global Long-Acting Insulin Analogue Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 88. Global Long-Acting Insulin Analogue Revenue Market Share Forecast by Type (2023-2028)

Table 89. Global Long-Acting Insulin Analogue Sales Forecast by Application (2023-2028) & (K Units)

Table 90. Global Long-Acting Insulin Analogue Sales Market Share Forecast by Application (2023-2028)

Table 91. Global Long-Acting Insulin Analogue Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 92. Global Long-Acting Insulin Analogue Revenue Market Share Forecast by Application (2023-2028)

Table 93. Novo Nordisk Basic Information, Long-Acting Insulin Analogue Manufacturing Base, Sales Area and Its Competitors

Table 94. Novo Nordisk Long-Acting Insulin Analogue Product Offered

Table 95. Novo Nordisk Long-Acting Insulin Analogue Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 96. Novo Nordisk Main Business

Table 97. Novo Nordisk Latest Developments

Table 98. Sanofi Basic Information, Long-Acting Insulin Analogue Manufacturing Base, Sales Area and Its Competitors

Table 99. Sanofi Long-Acting Insulin Analogue Product Offered

Table 100. Sanofi Long-Acting Insulin Analogue Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 101. Sanofi Main Business

Table 102. Sanofi Latest Developments

Table 103. Eli Lilly and Company Basic Information, Long-Acting Insulin Analogue Manufacturing Base, Sales Area and Its Competitors

Table 104. Eli Lilly and Company Long-Acting Insulin Analogue Product Offered

Table 105. Eli Lilly and Company Long-Acting Insulin Analogue Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 106. Eli Lilly and Company Main Business

Table 107. Eli Lilly and Company Latest Developments

Table 108. Gan and Lee Pharmaceuticals Basic Information, Long-Acting Insulin Analogue Manufacturing Base, Sales Area and Its Competitors

Table 109. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product Offered

Table 110. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)



Table 111. Gan and Lee Pharmaceuticals Main Business

Table 112. Gan and Lee Pharmaceuticals Latest Developments

Table 113. The United Laboratories International Holdings Basic Information, Long-Acting Insulin Analogue Manufacturing Base, Sales Area and Its Competitors

Table 114. The United Laboratories International Holdings Long-Acting Insulin Analogue Product Offered

Table 115. The United Laboratories International Holdings Long-Acting Insulin Analogue Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 116. The United Laboratories International Holdings Main Business

Table 117. The United Laboratories International Holdings Latest Developments

Table 118. Tonghua Dongbao Pharmaceutical Basic Information, Long-Acting Insulin Analogue Manufacturing Base, Sales Area and Its Competitors

Table 119. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product Offered

Table 120. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 121. Tonghua Dongbao Pharmaceutical Main Business

Table 122. Tonghua Dongbao Pharmaceutical Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Long-Acting Insulin Analogue
- Figure 2. Long-Acting Insulin Analogue Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Long-Acting Insulin Analogue Sales Growth Rate 2017-2028 (K Units)
- Figure 7. Global Long-Acting Insulin Analogue Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. Long-Acting Insulin Analogue Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Insulin Glargine
- Figure 10. Product Picture of Insulin Detemir
- Figure 11. Product Picture of Insulin Degludec
- Figure 12. Global Long-Acting Insulin Analogue Sales Market Share by Type in 2021
- Figure 13. Global Long-Acting Insulin Analogue Revenue Market Share by Type (2017-2022)
- Figure 14. Long-Acting Insulin Analogue Consumed in Type 2 Diabetes
- Figure 15. Global Long-Acting Insulin Analogue Market: Type 2 Diabetes (2017-2022) & (K Units)
- Figure 16. Long-Acting Insulin Analogue Consumed in Type 1 Diabetes
- Figure 17. Global Long-Acting Insulin Analogue Market: Type 1 Diabetes (2017-2022) & (K Units)
- Figure 18. Long-Acting Insulin Analogue Consumed in Gestational Diabetes
- Figure 19. Global Long-Acting Insulin Analogue Market: Gestational Diabetes (2017-2022) & (K Units)
- Figure 20. Long-Acting Insulin Analogue Consumed in Other Diabetes
- Figure 21. Global Long-Acting Insulin Analogue Market: Other Diabetes (2017-2022) & (K Units)
- Figure 22. Global Long-Acting Insulin Analogue Sales Market Share by Application (2017-2022)
- Figure 23. Global Long-Acting Insulin Analogue Revenue Market Share by Application in 2021
- Figure 24. Long-Acting Insulin Analogue Revenue Market by Company in 2021 (\$ Million)
- Figure 25. Global Long-Acting Insulin Analogue Revenue Market Share by Company in 2021

Figure 26. Global Long-Acting Insulin Analogue Sales Market Share by Geographic Region (2017-2022)

Figure 27. Global Long-Acting Insulin Analogue Revenue Market Share by Geographic Region in 2021

Figure 28. Global Long-Acting Insulin Analogue Sales Market Share by Region (2017-2022)

Figure 29. Global Long-Acting Insulin Analogue Revenue Market Share by Country/Region in 2021

Figure 30. Americas Long-Acting Insulin Analogue Sales 2017-2022 (K Units)

Figure 31. Americas Long-Acting Insulin Analogue Revenue 2017-2022 (\$ Millions)

Figure 32. APAC Long-Acting Insulin Analogue Sales 2017-2022 (K Units)

Figure 33. APAC Long-Acting Insulin Analogue Revenue 2017-2022 (\$ Millions)

Figure 34. Europe Long-Acting Insulin Analogue Sales 2017-2022 (K Units)

Figure 35. Europe Long-Acting Insulin Analogue Revenue 2017-2022 (\$ Millions)

Figure 36. Middle East & Africa Long-Acting Insulin Analogue Sales 2017-2022 (K Units)

Figure 37. Middle East & Africa Long-Acting Insulin Analogue Revenue 2017-2022 (\$ Millions)

Figure 38. Americas Long-Acting Insulin Analogue Sales Market Share by Country in 2021

Figure 39. Americas Long-Acting Insulin Analogue Revenue Market Share by Country in 2021

Figure 40. United States Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 41. Canada Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 42. Mexico Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 43. Brazil Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 44. APAC Long-Acting Insulin Analogue Sales Market Share by Region in 2021

Figure 45. APAC Long-Acting Insulin Analogue Revenue Market Share by Regions in 2021

Figure 46. China Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 47. Japan Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 48. South Korea Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 49. Southeast Asia Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 50. India Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 51. Australia Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 52. Europe Long-Acting Insulin Analogue Sales Market Share by Country in 2021

Figure 53. Europe Long-Acting Insulin Analogue Revenue Market Share by Country in 2021

Figure 54. Germany Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 55. France Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 56. UK Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 57. Italy Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 58. Russia Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 59. Middle East & Africa Long-Acting Insulin Analogue Sales Market Share by Country in 2021

Figure 60. Middle East & Africa Long-Acting Insulin Analogue Revenue Market Share by Country in 2021

Figure 61. Egypt Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 62. South Africa Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 63. Israel Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 64. Turkey Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 65. GCC Country Long-Acting Insulin Analogue Revenue Growth 2017-2022 (\$ Millions)

Figure 66. Manufacturing Cost Structure Analysis of Long-Acting Insulin Analogue in 2021

Figure 67. Manufacturing Process Analysis of Long-Acting Insulin Analogue

Figure 68. Industry Chain Structure of Long-Acting Insulin Analogue

Figure 69. Channels of Distribution

Figure 70. Distributors Profiles

## I would like to order

Product name: Global Long-Acting Insulin Analogue Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/G53C322AE487EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G53C322AE487EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970